Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854410 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1KMT2ABACE1NOS3 | |
| SCHEMBL22031958 | 0.82 | KDM4E (0.37) | KDM4EALDH1A1KMT2ABACE1F2 | |
| SCHEMBL20288409 | 0.81 | XPO1 (0.36) | XPO1 | |
| SCHEMBL21139917 | 0.78 | CYP3A4 (0.37) | KDM4EALDH1A1KMT2AGAATSHR | |
| SCHEMBL12763753 | 0.77 | KIF11 (0.31) | KIF11XPO1 | |
| SCHEMBL22062851 | 0.74 | CYP1A2 (0.42) | KDM4EALDH1A1GAATSHRMCHR1 | |
| SCHEMBL25163406 | 0.74 | CYP11B2 (0.39) | ALDH1A1KMT2A | |
| SCHEMBL22489583 | 0.74 | CYP1A2 (0.45) | ALDH1A1GAATSHRXPO1HSD17B10 | |
| SCHEMBL14108794 | 0.74 | NOS3 (0.52) | KDM4EALDH1A1KMT2ABACE1NOS3 | |
| SCHEMBL29937121 | 0.74 | NOS3 (0.52) | KDM4EALDH1A1KMT2ABACE1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021152149-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-08-05 | — | — | WO | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | KDM4E 4302/4885ALDH1A1 3223/4885KMT2A 3065/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KDM4E 2522/4885ALDH1A1 476/4885KMT2A 2755/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | KDM4E 3543/4885ALDH1A1 2917/4885KMT2A 2941/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | KDM4E 553/4885ALDH1A1 1000/4885KMT2A 391/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | KDM4E 1390/4885ALDH1A1 838/4885KMT2A 2981/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KDM4E 3677/4885ALDH1A1 3682/4885KMT2A 2991/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | KDM4E 206/4885ALDH1A1 362/4885KMT2A 143/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | KDM4E 2655/4885ALDH1A1 193/4885KMT2A 3790/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | KDM4E 1442/4885ALDH1A1 823/4885KMT2A 4050/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | KDM4E 2655/4885ALDH1A1 193/4885KMT2A 3790/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KDM4E 2522/4885ALDH1A1 476/4885KMT2A 2755/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | KDM4E 2655/4885ALDH1A1 193/4885KMT2A 3790/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | KDM4E 3651/4885ALDH1A1 3208/4885KMT2A 2137/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KDM4E 3124/4885ALDH1A1 3258/4885KMT2A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.